Table 1.

Nine (9) anticancer inhibitory drugs analyzed in both the CGP and CCLE with primary clinical relevance to ovarian cancer and secondary clinical relevance to breast, and endometrial cancer.

Drug Name	Target(s)	Class
Erlotinib	EGFR	Kinase Inhibitor
Irinotecan	Topoisomerase	Cytotoxic
AZD0530	Src, ABL/BCR-ABL, EGFR	Kinase Inhibitor
AZD6244	MEK, ERK, MAPK	Kinase Inhibitor
PD0325901	MEK, RAF, MAPK	Kinase Inhibitor
Lapatinib	EGFR, HER2	Kinase Inhibitor
17-AAG	HSP90	Other
Sorafenib	KIT, PDGFRB, FLT3, FLT4, KDR, RAF1, BRAF	Kinase Inhibitor
Paclitaxel	Microtubules	Cytotoxic